This review demonstrates the association of minimal residual disease with relapse risk in acute leukemia, highlighting the role of advanced detection methodologies.
Key Points
MRD status is a significant predictor of relapse risk and overall survival in acute leukemia patients.
Utilizing techniques like real-time quantitative polymerase chain reaction and next-generation sequencing enhances MRD assessment.
Assessing MRD at key timepoints informs risk-adapted therapies and decisions for hematopoietic stem cell transplant.
Technological advancements have improved standardization in MRD assessments, though challenges remain.